ACA
RNXT icon

Affinity Capital Advisors’s RenovoRx RNXT Stock Holding History

Affinity Capital Advisors’s Portfolio RNXT Stock Details RNXT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$12.6K Hold
13,279
– – ﹤0.01% 203
2026
Q1 		$13.4K Hold
13,279
– – ﹤0.01% 181
2025
Q4 		$11.2K Hold
13,279
– – ﹤0.01% 173
2025
Q3 		$16.9K Hold
13,279
– – ﹤0.01% 153
2025
Q2 		$17.5K Hold
13,279
– – ﹤0.01% 158
2025
Q1 		$10.3K Hold
13,279
– – ﹤0.01% 153
2024
Q4 		$18.2K Hold
13,279
– – ﹤0.01% 150
2024
Q3 		$14.1K Hold
13,279
– – ﹤0.01% 151
2024
Q2 		$15K Hold
13,279
– – ﹤0.01% 145
2024
Q1 		$17.8K Hold
13,279
– – ﹤0.01% 150
2023
Q4 		$30.4K Hold
13,279
– – 0.01% 135
2023
Q3 		$17.7K Hold
13,279
– – ﹤0.01% 131
2023
Q2 		$30K Hold
13,279
– – 0.01% 132
2023
Q1 		$46.3K Sell
13,279
-1,980
-13% -$6.97K 0.01% 120
2022
Q4 		$35.9K Buy
15,259
+4,009
+36% +$7.66K 0.01% 106
2022
Q3 		$23K Buy
+11,250
New +$24.4K 0.01% 104

Other funds holding RNXT

MCRM
Midway Capital Research & Management Chicago, Illinois $126M AUM
SS
SBI Securities Tokyo, Japan $4.4B AUM 74.25% 1-Year Est. Return

Affinity Capital Advisors's RNXT Position: Q2 2026 in Review

Affinity Capital Advisors held its RenovoRx (RNXT) position steady in Q2 2026 at 13,279 shares worth $12.6K. The position accounts for ﹤0.01% of the portfolio, ranked #203.

Affinity Capital Advisors first reported a position in RNXT in Q3 2022 and has held it in 16 quarters since. The position peaked at $46.3K in Q1 2023. 3 funds tracked by Wall St. Rank hold RNXT as of Q2 2026.

  • Affinity Capital Advisors held 13,279 shares of RenovoRx worth $12.6K as of Q2 2026.
  • Affinity Capital Advisors left its RenovoRx share count unchanged in Q2 2026.
  • RenovoRx made up ﹤0.01% of Affinity Capital Advisors's portfolio in Q2 2026, its #203 holding.
  • Affinity Capital Advisors first reported a position in RenovoRx in Q3 2022 and has held it in 16 quarters since.
  • Affinity Capital Advisors's RenovoRx position peaked at $46.3K in Q1 2023.
  • 3 funds tracked by Wall St. Rank held RenovoRx as of Q2 2026.

Based on Affinity Capital Advisors's 13F filing for Q2 2026, filed 8 Jul 2026.